Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skeleton

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Skeleton. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-002174-30 Sponsor Protocol Number: B3D-US-GHCV Start Date*: 2005-09-09
    Sponsor Name:Eli Lilly and Company
    Full Title: The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women in Osteoporosis
    Medical condition: Oesteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001330-17 Sponsor Protocol Number: PET-COLINA_2013 Start Date*: 2013-06-23
    Sponsor Name:IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro
    Full Title: Comparison between diagnostic accuracy of [11C]-choline PET/CT and conventional imaging in prostate cancer patients
    Medical condition: Prostate adenocarcinoma accounts for 11% of all malignancies, with a total 2.6 million new cases / year estimated in Europe. Mortality rate is 30.6 / 100,000 persons/year. Prostate cancer general...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10066489 Progression of prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000514-21 Sponsor Protocol Number: AG-PH3 Start Date*: 2007-01-02
    Sponsor Name:CIS bio International
    Full Title: Multicenter, randomized, open-label, clinical study on the agreement of Scintimun® Granulocyte and labeled 99mTc-White Blood Cells in diagnosing infection/inflammation by immunoscintigraphy in peri...
    Medical condition: Patients with suspected or documented osteomyelitis in the peripheral skeleton including patients with loosening of joint prosthesis or diabetic foot. At least one of following signs or symptoms is...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-019216-20 Sponsor Protocol Number: AZ2010 Start Date*: 2010-05-01
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: "Effects of drug treatment with bisphosphonates (zoledronic acid) in the prevention of skeletal events in breast cancer patients with osteoporosis. Significant correlation with some biological para...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000814-31 Sponsor Protocol Number: CAIN457F3302 Start Date*: 2016-08-03
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: MAXIMISE (Managing AXIal Manifestations in Psoriatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52 week study to assess the efficacy and safety of sec...
    Medical condition: Axial Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) FR (Completed) GB (Completed) HU (Completed) EE (Completed) IE (Completed) BE (Completed) FI (Completed) DK (Prematurely Ended) DE (Completed) BG (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001189-87 Sponsor Protocol Number: SAKK96/12 Start Date*: 2017-07-18
    Sponsor Name:Swiss Group for Clinical Cancer Research
    Full Title: Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks - A Non-Inferiority Phase III trial
    Medical condition: Bone metastases from castration resistant prostate cancer or from breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012397-12 Sponsor Protocol Number: PTH1-84 Start Date*: 2009-07-16
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: Energy metabolism and the skeleton: reciprocal interplay.
    Medical condition: Post-menopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004738-33 Sponsor Protocol Number: STH 14463 Start Date*: 2007-03-21
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects. Subtitle: A 2-year randomised parallel group trial of alendronate, ibandronate and risedronate for postmeno...
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001524-37 Sponsor Protocol Number: F1J MC HMEF Start Date*: 2005-06-29
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome
    Medical condition: Fibromyalgia syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10016631 Fibromyalgia syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003151-11 Sponsor Protocol Number: ECD-TCZ-1-03/2012 Start Date*: 2012-09-27
    Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO
    Full Title: An open-label, single-arm, phase II, prospective, pilot study of tocilizumab in patients with Erdheim-Chester disease.
    Medical condition: Erdheim Chester patology
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10020118 Histiocytoses HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003214-27 Sponsor Protocol Number: UTOTXA_2016_01 Start Date*: 2017-02-09
    Sponsor Name:Irene Barrientos Ruiz
    Full Title: Randomized, double-blind, 3-arm trial to evaluate the impact of blood loss following administration of three tranexamic acid regimens in patients undergoing bone or soft tissue sarcomas.
    Medical condition: Oncological orthopedic surgery (bone and soft tissue sarcomas in the appendicular skeleton, pelvis and scapular girdle).
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039498 Bone sarcomas HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000242-20 Sponsor Protocol Number: EURAMOS 1 Start Date*: 2005-04-05
    Sponsor Name:SSG
    Full Title: A randomised trial of the European and American Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy
    Medical condition: Ostesarcoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) NO (Completed) BE (Completed) IE (Completed) AT (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004235-24 Sponsor Protocol Number: ABX-CT-303 Start Date*: 2021-06-09
    Sponsor Name:ABX GmbH
    Full Title: Phase III study of [18F]PSMA-1007 positron emission tomography for the detection of prostate cancer lesions in patients with biochemical recurrence after previous definitive treatment for localized...
    Medical condition: Suspicion of prostate cancer recurrence or persistence after previous definitive treatment, based on American Society for Radiation Oncology (ASTRO) criteria of 3 consecutive PSA rises and/or ASTRO...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021009-19 Sponsor Protocol Number: STH15466 Start Date*: 2010-09-21
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action. A two year open label single arm study of teriparatide in secondary care.
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10031282 Osteoporosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000087-25 Sponsor Protocol Number: A090913 Start Date*: 2007-10-22
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An open label pilot study of Zoledronate (Aclasta 5mg iv) in the treatment of Ankylosing Spondylitis
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001051-39 Sponsor Protocol Number: FMG-MM-02 Start Date*: 2012-11-15
    Sponsor Name:Kuopio University Hospital, Clinic of Internal Medicine/Center of Medicine
    Full Title: A prospective phase II study to assess immunophenotypic remission after three-drug in-duction followed by randomized stem cell mobilization, autologous stem cell transplantation and lenalidomide ma...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001355-76 Sponsor Protocol Number: UCL/13/0291 Start Date*: 2016-05-09
    Sponsor Name:University College London
    Full Title: Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma
    Medical condition: Solitary bone plasmacytoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035484 Plasmacytoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003926-10 Sponsor Protocol Number: CHUBX2017/32 Start Date*: 2019-02-13
    Sponsor Name:CHU de Bordeaux
    Full Title: Prospective comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the initial work-up of Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001325-28 Sponsor Protocol Number: GOIM21003 Start Date*: 2012-07-17
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: non-Pegylated liposomal doxrubicina (Myocet) + cyclophosphamide versus non pegylated liposomal doxorubicin (Myocet) + metronomic cyclophosphamide in metastatic breast cancer-a multicenter randomize...
    Medical condition: patients wiyh metastatic breast cancer her2 negative first line treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001038-32 Sponsor Protocol Number: 8-55-58102-002 Start Date*: 2012-09-07
    Sponsor Name:Ipsen Pharma
    Full Title: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY OF MAINTENANCE THERAPY WITH TASQUINIMOD IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WHO ARE NOT PROGRESSING...
    Medical condition: maintenance therapy in metastatic Castrate Resistant Prostate Cancer patients who are not progressing under/after a first line docetaxel based chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) DE (Completed) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 18:38:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA